-
Innovation Ranking
NewInnovation Ranking – Celldex Therapeutics Inc
Celldex Therapeutics Inc (Celldex) is a bio-pharmaceutical company that discovers, develops, and commercializes targeted immunotherapy and other biologics for the treatment of various types of cancers. The company’s developmental pipeline comprises therapeutic antibodies, antibody drug conjugates (ADCs), protein-based therapeutics, immune system modulators and vaccine for unmet medical needs. Its key products in development include CDX-1140; CDX-527, CDX-0159. Celldex’s products find application in the treatment of various indications such as brain cancer, triple negative breast cancer, lymphoma/leukemia, melanoma, and renal cell...
-
Product Insights
NewNet Present Value Model: Celldex Therapeutics Inc’s Barzolvolimab
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Insights
Innovation and Patenting activity of Celldex Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Celldex Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Elzovantinib in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Elzovantinib in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Elzovantinib in Metastatic Colorectal Cancer Drug Details: Elzovantinib (TPX-0022) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Varlilumab in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Varlilumab in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Varlilumab in Mantle Cell Lymphoma Drug Details: Varlilumab (CDX-1127) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CDX-1140 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CDX-1140 in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CDX-1140 in Endometrial Cancer Drug Details: CDX-1140 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CDX-1140 in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CDX-1140 in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CDX-1140 in Peritoneal Cancer Drug Details: CDX-1140 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Varlilumab in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Varlilumab in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Varlilumab in Marginal Zone B-cell Lymphoma Drug Details: Varlilumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CDX-1140 in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CDX-1140 in Epithelial Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CDX-1140 in Epithelial Ovarian Cancer Drug Details: CDX-1140 is under...